• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ADROPIN
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • ADDICTION & DOPAMINE
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • ANXIOLYTIC
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BIOMIMETIC HYDROXYAPATITE
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CDK5
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DEPERSONALIZATION
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING & THE BRAIN
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • GUT BRAIN AXIS
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HAIR REPIGMENTATION
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERALGESIA
      • HYPERINSULINEMIA
      • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INSULIN OXIDATIVE STRESS
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON OPIOD ANALGESICS
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SEX HORMONE BINDING GLOBULIN
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    DNA METHYLATION & AGING
    May 10, 2022
    REPAIRING DNA DOUBLE STRAND BREAKS
    May 10, 2022
    1. μ-Opposing actions of the κ–opiod Receptor
    2. Structure of the human κ–opiod Receptor in complex with JDTic
    3. The dynorphin/κ–opiod Receptor system and its role in psychiatric disorders
    4. Development of κ opiod Receptor antagonists
    5. Dynorphin is a specific endogenous ligand of the κ opiod Receptor
    6. Molecular cloning and tissue distribution of a putative member of the rat opiod Receptor gene family that is not a μ, δ or κ opiod Receptor type
    7. Molecular cloning of a rat κ opiod Receptor reveals sequence similarities to the μ and δ opiod Receptors
    8. Quantitative autoradiographic mapping of μ-, δ-and κ–opiod Receptors in knockout mice lacking the μ-opiod Receptor gene
    9. κ–opiod Receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction
    10. Molecular cloning and expression of a rat κ opiod Receptor
    11. Cloning of a human κ opiod Receptor from the brain
    12. Pharmacological properties of JDTic: A novel κ–opiod Receptor antagonist
    13. κ opiod Receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses
    14. μ-and κ–opiod Receptor-meiated opiod effects on social play in juvenile rats
    15. Antipruritic activity of the κ–opiod Receptor agonist, TRK-820
    16. Effects of κ–opiod Receptor ligands on intracranial self-stimulation in rats
    17. CI‐977, a novel and selective agonist for the κ‐opiod Receptor
    18. Depressive-like effects of the κ–opiod Receptor agonist salvinorin A on behavior and neurochemistry in rats
    19. Cellular mechanism for anti-analgesic action of agonists of the κ–opiod Receptor
    20. GEC1 interacts with the κ opiod Receptor and enhances expression of the Receptor
    21. Modulation of the behavioral and neurochemical effects of psychostimulants by κ‐opiod Receptor systems
    22. The role of κ–opiod Receptor activation in mediating antinociception and addiction
    23. 5′-Guanidinonaltrindole, a highly selective and potent κ–opiod Receptor antagonist
    24. The role of the dynorphin/κ opiod Receptor system in anxiety
    25. Structure and chromosomal mapping of genes for the mouse κ–opiod Receptor and an opiod Receptor homologue (MOR-C)
    26. Asymmetric synthesis of salvinorin A, a potent κ opiod Receptor agonist
    27. Formation of μ-/κ–opiod Receptor heterodimer is sex-dependent and mediates female-specific opiod analgesia
    28. The intrinsic antinociceptive effects of oxycodone appear to be κ–opiod Receptor mediated
    29. Neuropathic pain activates the endogenous κ opiod system in mouse spinal cord and induces opiod Receptor tolerance
    30. Isolation of a human κ opiod Receptor cDNA from placenta
    31. Antidepressant-like effects of κ–opiod Receptor antagonists in the forced swim test in rats
    32. Research and development of κ opiod Receptor agonists and δ opiod Receptor agonists
    33. Anxiolytic-like effects of κ–opiod Receptor antagonists in models of unlearned and learned fear in rats
    34. Discovery of aminobenzyloxyarylamides as κ opiod Receptor selective antagonists: application to preclinical development of a κ opiod Receptor antagonist Receptor …
    35. Distinct mechanisms for activation of the opiod Receptor-like 1 and κ–opiod Receptors by nociceptin and dynorphin A
    36. Localization of the κ opiod Receptor in lipid rafts
    37. Salvinorin A: a novel and highly selective κ–opiod Receptor agonist
    38. Big dynorphin as a putative endogenous ligand for the κ‐opiod Receptor
    39. Primary astroglial cultures derived from several rat brain regions differentially express μ, δ and κ opiod Receptor mRNA
    40. Quantitative autoradiography of μ-, δ-and κ1 opiod Receptors in κ–opiod Receptor knockout mice
    41. Studies toward the pharmacophore of salvinorin A, a potent κ opiod Receptor agonist
    42. U50, 488, a κ opiod Receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats
    43. Long term κ–opiod Receptor blockade following nor-binaltorphimine
    44. Identification of novel functionally selective κ–opiod Receptor scaffolds
    45. 2-Methoxymethyl-salvinorin B is a potent κ opiod Receptor agonist with longer lasting action in vivo than salvinorin A
    46. Systemic κ‐opiod Receptor antagonism by nor‐binaltorphimine reduces dependence‐induced excessive alcohol self‐administration in rats
    47. Synthesis and κ–opiod Receptor activity of furan-substituted salvinorin A analogues
    48. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ–opiod Receptor agonist: structural and functional …
    49. Endogenous κ–opiod Receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine
    50. The selective κ–opiod Receptor agonist U50, 488H attenuates voluntary ethanol intake in the rat
    51. Novel opiod cyclic tetrapeptides: Trp isomers of CJ‐15,208 exhibit distinct opiod Receptor agonism and short‐acting κ opiod Receptor antagonism
    52. μ-, δ-and κ–opiod Receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients
    53. Distribution of κ opiod Receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study
    54. Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of κ–opiod Receptor-1 knockout mice
    55. Potent antinociceptive effects of TRK-820, a novel κ–opiod Receptor agonist
    56. Decreased oral self‐administration of alcohol in κ‐opiod Receptor knock‐out mice
    57. κ–opiod Receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine
    58. The effects of spiradoline (U‐62066E), a κ‐opiod Receptor agonist, on neuroendocrine function in man
    59. Chemotype-selective modes of action of κ–opiod Receptor agonists
    60. The G protein–biased κ–opiod Receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo
    61. The expression of δ-and κ–opiod Receptor is enhanced during intestinal inflammation in mice
    62. Characterization of mechanical withdrawal responses and effects of μ-, δ-and κ–opiod agonists in normal and μ-opiod Receptor knockout mice
    63. Molecular interaction between butorphanol and κ–opiod Receptor
    64. κ–opiod Receptor is colocalized in GnRH and KNDy cells in the female ovine and rat brain
    65. Antidepressant-like effects of κ–opiod Receptor antagonists in Wistar Kyoto rats
    66. Exploration of the SAR connection between morphinan-and arylacetamide-based κ opiod Receptor (κOR) agonists using the strategy of bridging
    67. Hallucinatory and rewarding effect of salvinorin A in zebrafish: κ–opiod and CB1-cannabinoid Receptor involvement
    68. Neuroprotective actions of GR89696, a highly potent and selective κ‐opiod Receptor agonist
    69. Buprenorphine is a potent κ–opiod Receptor antagonist in pigeons and mice
    70. Functional interaction among opiod Receptor types: up-regulation of μ-and δ-opiod Receptor functions after repeated stimulation of κ–opiod Receptors
    71. Analgesia from a peripherally active κ–opiod Receptor agonist in patients with chronic pancreatitis
    72. Strategies for developing κ opiod Receptor agonists for the treatment of pain with fewer side effects
    73. Agonist‐induced phosphorylation of the κ‐opiod Receptor
    74. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and κ–opiod Receptor agonists
    75. Isolation of a novel cDNA encoding a putative membrane Receptor with high homology to the cloned μ, δ, and κ opiod Receptors
    76. Sex-related differences in mechanical nociception and antinociception produced by μ-and κ–opiod Receptor agonists in rats
    77. Bi-directional heterologous desensitization between the major HIV-1 co-Receptor CXCR4 and the κ–opiod Receptor
    78. Disruption of the κ–opiod Receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488 H …
    79. Toward a structure-based model of salvinorin A recognition of the κ–opiod Receptor
    80. Regional, developmental, and cell cycle‐dependent differences in μ, δ, and κ‐opiod Receptor expression among cultured mouse astrocytes
    81. Synthesis and evaluation of 11C-LY2795050 as a κ–opiod Receptor antagonist radiotracer for PET imaging
    82. Gz coupling to the rat κ–opiod Receptor
    83. Noribogaine is a G-protein biased κ–opiod Receptor agonist
    84. Involvement of the κ–opiod Receptor in the anxiogenic-like effect of CP 55,940 in male rats
    85. Detection of opiod Receptor mRNA by RT-PCR reveals alternative splicing for the δ-and κ–opiod Receptors
    86. Autoradiography of [3H] U-69593 binding sites in rat brain: evidence for κ opiod Receptor subtypes
    87. LPK-26, a novel κ–opiod Receptor agonist with potent antinociceptive effects and low dependence potential
    88. Hippocampal dynorphin B injections impair spatial learning in rats: a κ–opiod Receptor-mediated effect
    89. PD117302: a selective agonist for the κ‐opiod Receptor
    90. Long-acting κ opiod antagonists disrupt Receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase
    91. Double in situ hybridization study on coexistence of μ-, δ-and κ–opiod Receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia
    92. Norbinaltorphimine, a selective κ–opiod Receptor antagonist, induces an itch-associated response in mice
    93. Enhanced κ–opiod Receptor-mediated analgesia by antisense targeting the σ1 Receptor
    94. Differential agonist regulation of the human κ‐opiod Receptor
    95. δ-, but not μ-and κ-, opiod Receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury
    96. κ–opiod Receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals
    97. The μ‐opiod Receptor agonist morphine, but not agonists at δ‐or κ‐opiod Receptors, induces peripheral antinociception mediated by cannabinoid Receptors
    98. … -based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the κ–opiod Receptor
    99. Mechanisms of agonist-induced down-regulation of the human κ–opiod Receptor: internalization is required for down-regulation
    100. Dynorphin peptides differentially regulate the human κ opiod Receptor
    101. Functional effects of systemically administered agonists and antagonists of μ, δ, and κ opiod Receptor subtypes on body temperature in mice
    102. Murine chromosomal location of the μ and κ opiod Receptor genes
    103. Duration of action of a broad range of selective κ–opiod Receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation
    104. Receptor‐selective changes in µ‐, δ‐and κ‐opiod Receptors after chronic naltrexone treatment in mice
    105. Synthesis of CJ-15,208, a novel κ–opiod Receptor antagonist
    106. Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ–opiod Receptor agonists
    107. Chronic muscle pain induced by repeated acid injection is reversed by spinally administered μ-and δ-, but not κ-, opiod Receptor agonists
    108. κ opiod Receptor ligands regulate angiogenesis in development and in tumours
    109. Phosphorylation of a carboxyl-terminal serine within the κ–opiod Receptor produces desensitization and internalization
    110. Association of in vivo κ–opiod Receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology
    111. Autoradiographic mapping of the opiod Receptor-like 1 (ORL1) Receptor in the brains of μ-, δ-or κ–opiod Receptor knockout mice
    112. Transformation of a κ–opiod Receptor Antagonist to a κ-Agonist by Transfer of a Guanidinium Group from the 5 ‘-to 6 ‘-Position of Naltrindole
    113. Modulation of anxiety-related behaviors by μ-and κ–opiod Receptor agonists depends on the social status of mice
    114. U50, 488H-induced internalization of the human κ opiod Receptor involves a β-arrestin-and dynamin-dependent mechanism: κ Receptor internalization is not …
    115. Repeated exposure to the κ–opiod Receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity
    116. Mechanism of diuretic action of U-62,066 E, a κ opiod Receptor agonist
    117. Anxiety and ethanol consumption in victorious and defeated mice; effect of κ–opiod Receptor activation
    118. The atomistic level structure for the activated human κ–opiod Receptor bound to the full Gi protein and the MP1104 agonist
    119. DAMGO, a μ‐opiod Receptor selective ligand, distinguishes between μ‐and κ‐opiod Receptors at a different region from that for the distinction between μ‐and δ …
    120. Properties of a κ–opiod Receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual Gα subunit and is similar to that of other …
    121. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ-and κ–opiod Receptor agonist and δ-opiod Receptor antagonist
    122. Suppression of the GnRH pulse generator by neurokinin B involves a κ–opiod Receptor-dependent mechanism
    123. Agonist-promoted Lys63-linked polyubiquitination of the human κ–opiod Receptor is involved in Receptor down-regulation
    124. Suppression of morphine withdrawal by electroacupuncture in rats: dynorphin and κ–opiod Receptor implicated
    125. Stress-induced activation of the dynorphin/κ–opiod Receptor system in the amygdala potentiates nicotine conditioned place preference
    126. 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ–opiod Receptor agonist that inhibits arrestin recruitment
    127. Pharmacology and anti‐addiction effects of the novel κ opiod Receptor agonist M esyl S al B, a potent and long‐acting analogue of salvinorin A
    128. Essential structure of the κ opiod Receptor agonist nalfurafine for binding to the κ Receptor
    129. Pharmacological properties of TRK-820 on cloned μ-, δ-and κ–opiod Receptors and nociceptin Receptor
    130. Agonist-dependent desensitization of the κ opiod Receptor by G protein Receptor kinase and β-arrestin
    131. The κ opiod Receptor and food intake
    132. Identification of short-acting κ–opiod Receptor antagonists with anxiolytic-like activity
    133. Hypothalamic κ–opiod Receptor modulates the orexigenic effect of ghrelin
    134. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte: involvement of κ–opiod Receptor
    135. Central nicotine induces browning through hypothalamic κ opiod Receptor
    136. Central κ–opiod Receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studies
    137. Antagonists of the κ‐opiod Receptor enhance allodynia in rats and mice after sciatic nerve ligation
    138. A regulatory variation in OPRK1, the gene encoding the κ–opiod Receptor, is associated with alcohol dependence
    139. κ–opiod Receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opiod treatments
    140. κ–opiod Receptor agonist U50, 488H modulates cocaine and morphine self-administration in drug-naive rats and mice
    141. Hypoxia induces internalization of κ–opiod Receptor
    142. Immunomodulatory action of class μ, δ-and κ–opiod Receptor agonists in mice
    143. L-type Ca2+ channel modulation by dihydropyridines potentiates κ–opiod Receptor agonist induced acute analgesia and inhibits development of tolerance in rats
    144. Immunosuppression by δ-opiod antagonist naltrindole: δ-and triple μ/δ/κ–opiod Receptor knockout mice reveal a nonopiod activity
    145. Exposure to the selective κ–opiod Receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats
    146. Analgesic efficacy of peripheral κ–opiod Receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective …
    147. Copb1-facilitated axonal transport and translation of κ opiod–Receptor mRNA
    148. Pulsed magnetic field induced “analgesia” in the land snail, Cepaea nemoralis, and the effects of μ, δ, and κ opiod Receptor agonists/antagonists
    149. Increased κ–opiod Receptor expression and function during chronic visceral hypersensitivity
    150. Role of κ–opiod Receptor activation in pharmacological preconditioning of swine
    151. Antidepressive effects of the κ–opiod Receptor agonist salvinorin A in a rat model of anhedonia
    152. Region selective up-regulation of μ-, δ-and κ–opiod Receptors but not opiod Receptor-like 1 Receptors in the brains of enkephalin and dynorphin knockout mice
    153. Stimulation of κ–opiod Receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis
    154. Targeting opiod Receptor signaling in depression: do we need selective κ opiod Receptor antagonists?
    155. κ–opiod Receptor activation in dopamine neurons disrupts behavioral inhibition
    156. In situ hybridization study of μ-and κ–opiod Receptor mRNAs in the rat spinal cord and dorsal root ganglia
    157. Chemical coding of neurons expressing δ-and κ–opiod Receptor and type I vanilloid Receptor immunoreactivities in the porcine ileum
    158. Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/κ–opiod Receptor-mediated mechanism without …
    159. Allosterism within δ opiod–κ opiod Receptor Heteromers in Peripheral Sensory Neurons: Regulation of κ opiod Agonist Efficacy
    160. κ–opiod Receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes
    161. Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opiod Receptor agonist
    162. Receptor occupancy of the κ–opiod antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050
    163. Axonal mRNA transport and localized translational regulation of κ–opiod Receptor in primary neurons of dorsal root ganglia
    164. Pharmacological activities of optically pure enantiomers of the κ opiod agonist, U50, 488, and its cis diastereomer: evidence for three κ Receptor subtypes
    165. κ–opiod Receptor stimulation modulates TLR4/NF-κB signaling in the rat heart subjected to ischemia–reperfusion
    166. Regulation of mouse κ opiod Receptor gene expression by retinoids
    167. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ–opiod Receptor
    168. The macrocyclic tetrapeptide [D‐T rp] CJ‐15,208 produces short‐acting κ opiod Receptor antagonism in the CNS after oral administration
    169. Effects of peripherally restricted κ opiod Receptor agonists on pain-related stimulation and depression of behavior in rats
    170. κ opiod Receptor-mediated analgesia in the developing rat
    171. Antiarrhythmic effect mediated by κ–opiod Receptor is associated with Cx43 stabilization
    172. Phosphatidylinositol‐3 kinase is distinctively required for µ‐, but not κ‐opiod Receptor‐induced activation of c‐Jun N‐terminal kinase
    173. κ–opiod Receptor participates of NSAIDs peripheral antinociception
    174. Selective changes in μ, δ and ϰ opiod Receptor binding in certain limbic regions of the brain in Alzheimer’s disease patients
    175. Sequence of κ–opiod Receptor cDNA in the R1. 1 thymoma cell line
    176. Development of novel quinoxaline-based κ–opiod Receptor agonists for the treatment of neuroinflammation
    177. Prodynorphin, proenkephalin and κ opiod Receptor mRNA responses to acute “binge” cocaine
    178. Effects of atypical κ–opiod Receptor agonists on intrathecal morphine-induced itch and analgesia in primates
    179. Repeated stress dysregulates κ–opiod Receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism
    180. Molecular switches of the κ opiod Receptor triggered by 6′-GNTI and 5′-GNTI
    181. Sodium channel blocking actions of the κ–opiod Receptor agonist U50, 488 contribute to its visceral antinociceptive effects
    182. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the κ–opiod Receptor agonist U69593
    183. An electrophysiological basis for the antiarrhythmic actions of the κ–opiod Receptor agonist U-50,488 H
    184. In situ hybridization study of κ–opiod Receptor mRNA in the rat brain
    185. Effects of a newly synthesized κ–opiod Receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats
    186. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ–opiod Receptor antagonist JDTic
    187. Effects of the κ–opiod Receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat
    188. opiod Receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of κ opiod Receptors
    189. Lack of cross-tolerance between U69, 593 and bremazocine suggest κ–opiod Receptor multiplicity in mice
    190. Impact of pharmacological manipulation of the κ–opiod Receptor system on self-grooming and anhedonic-like behaviors in male mice
    191. Test–retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opiod Receptor
    192. Effects of peripheral κ opiod Receptor activation on inflammatory mechanical hyperalgesia in male and female rats
    193. μ-, δ-, and κ–opiod Receptor agonists selectively modulate sexual behaviors in the female rat: differential dependence on progesterone
    194. Structure and expression of a rat κ opiod Receptor gene
    195. Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by κ–opiod Receptor agonist
    196. Investigation of inactive-state κ opiod Receptor homodimerization via single-molecule microscopy using new antagonistic fluorescent probes
    197. N-Glycosylation of the Human κ opiod Receptor Enhances Its Stability but Slows Its Trafficking along the Biosynthesis Pathway
    198. Further evidence for the implication of a κ–opiod Receptor mechanism in the production of psychological stress-induced analgesia
    199. Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ–opiod Receptor/β-catenin signaling axis
    200. κ–opiod Receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative …
    201. Feeding responses to μ-, δ-and κ–opiod Receptor agonists in the meat-type chick
    202. κ–opiod Receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway
    203. Constraining endomorphin-1 by β, α-hybrid dipeptide/heterocycle scaffolds: identification of a novel κ–opiod Receptor selective partial agonist
    204. G protein signaling–biased agonism at the κ–opiod Receptor is maintained in striatal neurons
    205. Dynorphin and κ–opiod Receptor dysregulation in the dopaminergic reward system of human alcoholics
    206. Identification of the three-dimensional pharmacophore of κ–opiod Receptor agonists
    207. Antinociceptive and Adverse Effects of µ‐and κ‐opiod Receptor Agonists: A Comparison of Morphine and U50488‐H
    208. Conformational analysis and automated Receptor docking of selective arylacetamide-based κ–opiod agonists
    209. Beneficial effects of the κ opiod Receptor agonist U-50488H in experimental acute brain and spinal cord injury
    210. Effect of κ–opiod Receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells
    211. An improved antagonist radiotracer for the κ–opiod Receptor: Synthesis and characterization of 11C-LY2459989
    212. κ–opiod Receptor agonists modulate visceral nociception at a novel, peripheral site of action
    213. Visualizing preference of G protein-coupled Receptor kinase 3 for the process of κ–opiod Receptor sequestration
    214. μ-, δ-and κ–opiod Receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate
    215. Sex difference in κ–opiod Receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5′-O-(3-[35S] thiotriphosphate) binding in …
    216. Early role of the κ opiod Receptor in ethanol-induced reinforcement
    217. Structure–Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ opiod Receptor
    218. Prodynorphin and κ opiod Receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders
    219. Post-transcriptional regulation of mouse κ–opiod Receptor expression
    220. Trial-selective effects of U50, 488H, a κ–opiod Receptor agonist, on consummatory successive negative contrast
    221. Development and in vivo evaluation of a κ–opiod Receptor agonist as a PET radiotracer with superior imaging characteristics
    222. Anti-arrhythmic effect of κ–opiod Receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway
    223. Anti‐nociception mediated by a κ opiod Receptor agonist is blocked by a δ Receptor agonist
    224. Voluntary ethanol intake predicts κ–opiod Receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques
    225. Spinal κ–opiod Receptor-mediated antinociception is stimulus-specific
    226. Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of κ opiod Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via …
    227. Neuroanatomical and neuropharmacological study of opiod pathways in the mesencephalic tectum: effect of μ1-and κ–opiod Receptor blockade on escape behavior …
    228. Regulation of κ–opiod Receptor signaling in peripheral sensory neurons in vitro and in vivo
    229. Activity profiles of dalargin and its analogues in μ‐, δ‐ and κ‐opiod Receptor selective bioassays
    230. Elucidation of conformational states, dynamics, and mechanism of binding in human κ–opiod Receptor complexes
    231. Modeling of κ–opiod Receptor/agonists interactions using pharmacophore-based and docking simulations
    232. Prenatal ethanol increases ethanol intake throughout adolescence, alters ethanol‐mediated aversive learning, and affects μ but not δ or κ opiod Receptor mRNA …
    233. Presence of μ and κ opiod Receptor mRNAs in galanin but not in GnRH neurons in the female rat
    234. Prolonged opportunity for ischemic neuroprotection with selective κ–opiod Receptor agonist in rats
    235. Hyaluronic acid induces activation of the κ–opiod Receptor
    236. The novel κ–opiod Receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice
    237. Characterization of κ–opiod Receptor transcripts expressed by T cells and macrophages
    238. 8-epi-Salvinorin B: crystal structure and affinity at the κ opiod Receptor
    239. Suppression of cAMP by phosphoinositol/Ca2+ pathway in the cardiac κ–opiod Receptor
    240. Endogenous κ opiod Receptor Systems Modulate the Responsiveness of Mesoaccumbal Dopamine Neurons to Ethanol
    241. Effects of κ–opiod Receptor agonists on long-term cocaine use and dopamine neurotransmission
    242. Blockade of U50, 488H analgesia by antisense oligodeoxynucleotides to a κ–opiod Receptor
    243. Intrinsic relative activities of κ opiod agonists in activating Gα proteins and internalizing Receptor: Differences between human and mouse Receptors
    244. … of CYX-6, a potent μ-opiod Receptor agonist, a δ-and κ–opiod Receptor antagonist and a biased ligand at μ, δ & κ–opiod Receptors, evokes antinociception with …
    245. U-50,488 H, a κ–opiod Receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice
    246. Butorphanol dependence increases hippocampal κ‐opiod Receptor gene expression
    247. Buprenorphine is an Antagonist at the ϰ opiod Receptor
    248. κ–opiod Receptor modulation of accumbal dopamine concentration during operant ethanol self-administration
    249. Effects of κ‐opiod Receptor stimulation in the heart and the involvement of protein kinase C
    250. Differential effects of μ-, δ-, and κ–opiod Receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat
    251. Antisense oligodeoxynucleotide to a δ-opiod Receptor selectivily blocks the spinal antinociception induced by δ-, but not μ-or κ–opiod Receptor agonists in the mouse
    252. The protective effects of κ–opiod Receptor stimulation in hypoxic pulmonary hypertension involve inhibition of autophagy through the AMPK-MTOR pathway
    253. Response of neuropeptide Y-induced feeding to μ-, δ-and κ–opiod Receptor antagonists in the neonatal chick
    254. Design of a stable cyclic peptide analgesic derived from sunflower seeds that targets the κ–opiod Receptor for the treatment of chronic abdominal pain
    255. Effect of repeated administration of TRK-820, a κ–opiod Receptor agonist, on tolerance to its antinociceptive and sedative actions
    256. Tyrosine phosphorylation of Kir3 following κ–opiod Receptor activation of p38 MAPK causes heterologous desensitization
    257. Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opiod Receptor antagonists
    258. Roles of KATP channels in delayed cardioprotection and intracellular Ca2+ in the rat heart as revealed by κ‐opiod Receptor stimulation with U50,488H
    259. N-methylacetamide analog of salvinorin A: a highly potent and selective κ–opiod Receptor agonist with oral efficacy
    260. Localization of κ–opiod Receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord
    261. κ–opiod Receptor activation protects against myocardial ischemia-reperfusion injury via AMPK/Akt/eNOS signaling activation
    262. Analyzing interaction of μ-, δ-and κ–opiod Receptor gene variants on alcohol or drug dependence using a pattern discovery-based method
    263. … morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its δ-and κ–opiod Receptor …
    264. NMR and modeling studies of a synthetic extracellular loop II of the κ opiod Receptor in a DPC micelle
    265. Down-regulation of the tumour suppressor κ–opiod Receptor predicts poor prognosis in hepatocellular carcinoma patients
    266. Syntheses of immobilized G protein-coupled Receptor chromatographic stationary phases: characterization of immobilized μ and κ opiod Receptors
    267. Determination of sites of U50, 488H-promoted phosphorylation of the mouse κ opiod Receptor (KOPR): disconnect between KOPR phosphorylation and internalization
    268. Cloning and promoter mapping of mouse κ opiod Receptor gene
    269. Central and peripheral actions of the novel κ‐opiod Receptor agonist, EMD 60400
    270. Mouse κ–opiod Receptor mRNA differential transport in neurons
    271. Electroacupuncture relieves labour pain and influences the spinal dynorphin/κ–opiod Receptor system in rats
    272. Novel 18F-labeled κ–opiod Receptor antagonist as PET radiotracer: synthesis and in vivo evaluation of 18F-LY2459989 in nonhuman primates
    273. Effects of salvinorin A, a κ–opiod hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ–Receptor homology to humans
    274. … -50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50, 488H-induced down-regulation of the human κ opiod Receptor by enhancing its …
    275. κ–opiod Receptor gene as a predictor of response in a cocaine vaccine clinical trial
    276. Differential regulation of the human κ opiod Receptor by agonists: etorphine and levorphanol reduced dynorphin A-and U50, 488H-induced internalization and …
    277. Effects of the local administration of selective μ-, δ-and κ–opiod Receptor agonists on osteosarcoma-induced hyperalgesia
    278. μ‐opiod Agonist Inhibition of κ‐opiod Receptor‐Stimulated Extracellular Signal‐Regulated Kinase Phosphorylation Is Dynamin‐Dependent in C6 Glioma Cells
    279. Comparison of G-protein activation in the brain by μ-, δ-, and κ–opiod Receptor agonists in μ-opiod Receptor knockout mice
    280. Drug design and synthesis of a novel κ opiod Receptor agonist with an oxabicyclo [2.2. 2] octane skeleton and its pharmacology
    281. Distribution of κ‐opiod Receptor in the Pulmonary Artery and its Changes During Hypoxia
    282. Neuroprotective κ–opiod Receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats
    283. Cu-Catalyzed N-arylation of oxazolidinones: An efficient synthesis of the κ–opiod Receptor agonist CJ-15161
    284. Novel malonamide derivatives as potent κ opiod Receptor agonists
    285. Changes in the brain κ–opiod Receptor levels of rats in withdrawal from physical dependence upon butorphanol
    286. Effects of heat shock protein 70 activation by metabolic inhibition preconditioning or κ–opiod Receptor stimulation on Ca2+ homeostasis in rat ventricular myocytes …
    287. Identification of arodyn, a novel acetylated dynorphin A-(1− 11) analogue, as a κ opiod Receptor antagonist
    288. Effects of intrathecal κ–opiod Receptor agonist on morphine-induced itch and antinociception in mice
    289. μ but not δ and κ opiod Receptor involvement in ventrolateral orbital cortex opiod-evoked antinociception in formalin test rats
    290. Quaternary ammonium salt of U50488H, a new κ–opiod Receptor agonist, protects rat heart against ischemia/reperfusion injury
    291. Heterologous µ‐opiod Receptor adaptation by repeated stimulation of κ‐opiod Receptor: up‐regulation of G‐protein activation and antinociception
    292. In vivo and in vitro characterization of naltrindole-derived ligands at the κ–opiod Receptor
    293. Effects of morphine in rats treated chronically with U-50,488 H, a κ opiod Receptor agonist
    294. Peripheral component in the enhanced antinociceptive effect of systemic U-69,593, a κ–opiod Receptor agonist in mononeuropathic rats
    295. Changes in spinal δ and κ opiod systems in mice deficient in the A2A Receptor gene
    296. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by μ-, δ-and κ–opiod Receptor agonists in the rat brain: Regulation by chronic morphine and opiod …
    297. Gastric effects of μ-, δ-and κ–opiod Receptor agonists on brainstem unitary responses in the neonatal rat
    298. δ, μ, and κ opiod Receptor agonists inhibit dopamine overflow in rat neostriatal slices
    299. Pharmacological properties of R-84760, a novel κ–opiod Receptor agonist
    300. Amygdalar κ–opiod Receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opiod abstinence
    301. Complete knockout of the nociceptin/orphanin FQ Receptor in the rat does not induce compensatory changes in μ, δ and κ opiod Receptors
    302. Determination of the in vivo selectivity of a new κ–opiod Receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey
    303. Highly potent and selective new diphenethylamines interacting with the κ–opiod Receptor: synthesis, pharmacology, and structure–activity relationships
    304. Analysis of the antinociceptive actions of the κ–opiod agonist enadoline (CI-977) in neonatal and adult rats: comparison to κ–opiod Receptor mRNA ontogeny
    305. Antinociceptive effect of a κ–opiod Receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy
    306. Chronic food restriction alters μ and κ opiod Receptor binding in the parabrachial nucleus of the rat: a quantitative autoradiographic study
    307. Agonist-Dependent and-Independent κ opiod Receptor phosphorylation: distinct phosphorylation patterns and different cellular outcomes
    308. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective κ‐opiod Receptor agonist
    309. κ–opiod Receptor effects of butorphanol in rhesus monkeys
    310. The association of genetic polymorphisms in the κ–opiod Receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone …
    311. Chronic cocaine increases κ‐opiod Receptor density: Lack of effect by selective dopamine uptake inhibitors
    312. N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: Selective and Nonbasic κ–opiod Receptor Ligands
    313. κ–opiod Receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats
    314. Effects of κ–opiod Receptor activation on myocardium
    315. Discovery of a Highly Selective and Potent κ opiod Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced …
    316. Up-regulation of RGS4 mRNA by opiod Receptor agonists in PC12 cells expressing cloned μ-or κ–opiod Receptors
    317. Antisense confirmation of μ-and κ–opiod Receptor mediation of morphine’s effects on body temperature in rats
    318. A highly selective κ–opiod Receptor agonist with low addictive potential and dependence liability
    319. Studies of dual promoters of mouse κ–opiod Receptor gene
    320. Enadoline, a selective κ–opiod Receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain
    321. κ–opiod Receptor stimulation reduces palmitate-induced apoptosis via Akt/eNOS signaling pathway
    322. Xylazine induced central antinociception mediated by endogenous opiods and μ-opiod Receptor, but not δ-or κ–opiod Receptors
    323. Purification and mass spectrometric analysis of the κ opiod Receptor
    324. κ–opiod Receptor stimulation improves endothelial function via Akt-stimulated NO production in hyperlipidemic rats
    325. Ischemic neuroprotection with selective κ–opiod Receptor agonist is gender specific
    326. κ–opiod Receptor as a key mediator in the regulation of appetitive 50-kHz ultrasonic vocalizations
    327. [11C]-MeJDTic: a novel radioligand for κ–opiod Receptor positron emission tomography imaging
    328. Novel signaling of dynorphin at κ–opiod Receptor/bradykinin B2 Receptor heterodimers
    329. … helical orientations among related G protein-coupled Receptors provide a novel mechanism for selectivity: studies with salvinorin A and the κ–opiod Receptor
    330. κ opiod Receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice
    331. Involvement of the κ–opiod Receptor in nitrous oxide-induced analgesia in mice
    332. Dissociable effects of the κ–opiod Receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by …
    333. Synthesis of an affinity ligand (‘UPHIT’) for in vivo acylation of the κ–opiod Receptor
    334. opiods in cancer: The κ‑opiod Receptor
    335. Netrin-1 signaling regulates de novo protein synthesis of κ opiod Receptor by facilitating polysomal partition of its mRNA
    336. Differential effects of μ-, δ-and κ–opiod Receptor agonists on the discriminative stimulus properties of cocaine in rats
    337. κ–opiod Receptor stimulation increases intracellular free calcium in isolated rat ventricular myocytes
    338. κ–opiod Receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma
    339. Effects of JDTic, a selective κ–opiod Receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion …
    340. Effects of Peripheral μ, δ, and κ–opiod Receptor Agonists on the Levels of Anxiety and Motor Activity of Rats
    341. Differential κ–opiod Receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation
    342. Modulation of glutamate release by a κ–opiod Receptor agonist in rodent and primate striatum
    343. Azepinone as a conformational constraint in the design of κ–opiod Receptor agonists
    344. Anticonvulsive effects of κ‐opiod Receptor modulation in an animal model of ethanol withdrawal
    345. κ–opiod Receptor stimulation improves endothelial function in hypoxic pulmonary hypertension
    346. Plant-Derived Cyclotides Modulate κ–opiod Receptor Signaling
    347. Modulation of humoral immune response by central administration of leucine-enkephalin: Effects of μ, δ and κ opiod Receptor antagonists
    348. 2, 4-Substituted bispidines as rigid hosts for versatile applications: from κ–opiod Receptor to metal coordination
    349. Anti-arrhythmic effects of κ–opiod Receptor and its changes in ischemia and reperfusion
    350. κ–opiod Receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells
    351. μ and κ opiod Receptor distribution in the monogamous titi monkey (Callicebus cupreus): Implications for social behavior and endocrine functioning
    352. [Nα-BenzylTyr,cyclo(d-Asp5,Dap8)]- dynorphin A-(1−11)NH2 Cyclized in the “Address” Domain Is a Novel κ–opiod Receptor Antagonist
    353. Effects of U-50,488 H, a κ–opiod Receptor agonist, on the learned helplessness model of depression in mice
    354. The selective κ–opiod Receptor agonist U50, 488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates
    355. Evidence for coupling of the κ opiod Receptor to brain GTPase
    356. A novel κ–opiod Receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice
    357. κ–opiod Receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells
    358. Ligands regulate cell surface level of the human κ opiod Receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement …
    359. Reactive oxygen species (ROS) generation is stimulated by κ opiod Receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 …
    360. The effect of activated κ–opiod Receptor (κ-OR) on the role of calcium sensing Receptor (CaSR) in preventing hypoxic pulmonary hypertension development
    361. κ–opiod Receptor mediates the antinociceptive effect of nitrous oxide in mice
    362. Retinoic acid-induced chromatin remodeling of mouse κ opiod Receptor gene
    363. Antagonism of κ opiod Receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence
    364. κ–opiod Receptor model in a phospholipid bilayer: Molecular dynamics simulation
    365. Cardioprotection with κ–opiod Receptor stimulation is associated with a slowing of cross-bridge cycling
    366. Influence of asimadoline, a new κ‐opiod Receptor agonist, on tubular water absorption and vasopressin secretion in man
    367. Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a δ-and κ–opiod Receptor agonist
    368. The adrenergic Receptor agonist, clonidine, potentiates the anti‐parkinsonian action of the selective κ‐opiod Receptor agonist, enadoline, in the monoamine‐depleted …
    369. Amygdala dynorphin/κ opiod Receptor system modulates depressive-like behavior in mice following chronic social defeat stress
    370. RGS2 and RGS4 proteins: New modulators of the κ–opiod Receptor signaling
    371. Disability of development of tolerance to morphine and U-50,488 H, a selective κ–opiod Receptor agonist, in neuropathic pain model mice
    372. … effect of a benzilidine-cyclohexanone analogue on a mouse model of chronic constriction injury-induced neuropathic pain: Participation of the κ–opiod Receptor and …
    373. κ–opiod regulation of thymocyte IL-7 Receptor and CC chemokine Receptor 2 expression
    374. Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline‐Based κ‐opiod Receptor (KOR) Agonists Designed for PET Studies
    375. Variants of κ–opiod Receptor gene and mRNA in alcohol-preferring and alcohol-avoiding mice
    376. Differentiation of δ, μ, and κ opiod Receptor agonists based on pharmacophore development and computed physicochemical properties
    377. The anticonvulsant action of CI-977, a selective κ–opiod Receptor agonist: a possible involvement of the glycine/NMDA Receptor complex
    378. A novel signaling pathway of nitric oxide on transcriptional regulation of mouse κ opiod Receptor gene
    379. … to confer cardioprotection and to increase the expression of heat-shock protein 70 by preconditioning with a κ–opiod Receptor agonist during ischaemia and …
    380. Effect of μ and κ opiod Receptor agonists on rat plasma corticosterone levels
    381. Activity of the δ-opiod Receptor is partially reduced, whereas activity of the κ–Receptor is maintained in mice lacking the μ-Receptor
    382. … neurotoxicity in mice via upregulation of dynorphin-mediated κ–opiod Receptor and downregulation of substance P-mediated neurokinin 1 Receptor
    383. Tyrosine phosphorylation of the κ–opiod Receptor regulates agonist efficacy
    384. Current κ opiod Receptor ligands and discovery of a new molecular scaffold as a κ opiod Receptor antagonist using pharmacophore-based virtual screening
    385. … of GEC1 protein and γ-aminobutyric acid type A (GABAA) Receptor-associated protein (GABARAP), two microtubule-associated proteins, on κ opiod Receptor …
    386. Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ–opiod Receptor Agonists with Anti-Inflammatory Activity in Vivo
    387. Discovery of peripheral κ–opiod Receptor agonists as novel analgesics
    388. GEC1-κ opiod Receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect
    389. Molecular modeling study of the differential ligand–Receptor interaction at the μ, δ and κ opiod Receptors
    390. Study of the involvement of K+ channels in the peripheral antinociception of the κ–opiod Receptor agonist bremazocine
    391. Regulation of mouse κ opiod Receptor gene expression by different 3′-untranslated regions and the effect of retinoic acid
    392. κ–opiod Receptor is involved in the cardioprotection induced by exercise training
    393. The G‐protein biased partial κ opiod Receptor agonist 6′‐GNTI blocks hippocampal paroxysmal discharges without inducing aversion
    394. … behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ–opiod Receptor agonist nalfurafine hydrochloride
    395. The μ-opiod activity of κ–opiod Receptor agonist compounds in the guinea pig ileum
    396. Cellular distribution of the mRNA for the κ–opiod Receptor in the human neocortex: a non-isotopic in situ hybridization study
    397. In Vivo Modulation of Post‐Spike Excitability in Vasopressin Cells by κ‐opiod Receptor Activation
    398. Topical κ‐opiod Receptor agonist asimadoline improves dermatitis in a canine model of atopic dermatitis
    399. Lack of effect of γ-hydroxybutyrate on μ, δ and κ opiod Receptor binding
    400. Role of κ—opiod Receptor in Hypoxic Pulmonary Artery Hypertension and Its Underlying Mechanism
    401. Treatment of cocaine craving with as-needed nalmefene, a partial κ opiod Receptor agonist: first clinical experience
    402. G protein coupled Receptor kinase-2 upregulation causes κ–opiod Receptor desensitization in diabetic heart
    403. Identity of the putative δ1-opiod Receptor as a δ–κ heteromer in the mouse spinal cord
    404. U-50488H, a selective κ–opiod Receptor agonist, improves carbon monoxide-induced delayed amnesia in mice
    405. A population pharmacokinetic and pharmacodynamic study of a peripheral κ–opiod Receptor agonist CR665 and oxycodone
    406. Protein kinase C-ε is a trigger of delayed cardioprotection against myocardial ischemia of κ–opiod Receptor stimulation in rat ventricular myocytes
    407. μ-and κ–opiod Receptor agonists produce peripheral inhibition of neurogenic plasma extravasation in rat skin
    408. A highly selective κ–opiod Receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro
    409. κ–opiod Receptor inhibition of calcium oscillations in spinal cord neurons
    410. A select set of opiod ligands induce up-regulation by promoting the maturation and stability of the rat κ–opiod Receptor in human embryonic kidney 293 cells
    411. Synthesis, biological evaluation, and Receptor docking simulations of 2-[(acylamino) ethyl]-1, 4-benzodiazepines as κ–opiod Receptor agonists endowed with …
    412. Modulation of the Neurotoxic Effects of Methamphetamine by the Selective κ‐opiod Receptor Agonist U69593
    413. Investigation of the μ‐and κ‐opiod Receptor activation by eight new synthetic opiods using the [35S]‐GTPγS assay: U‐47700, isopropyl U‐47700, U‐49900, U …
    414. Novel κ–opiod Receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation
    415. Activation of the κ–opiod Receptor in Caco-2 cells decreases interleukin-8 secretion
    416. Inhibitory and excitatory effects of μ-, δ-, and κ–opiod Receptor activation on breathing in awake turtles, Trachemys scripta
    417. Neurofilament proteins and cAMP pathway in brains of μ-, δ-or κ–opiod Receptor gene knock-out mice: effects of chronic morphine administration
    418. Design, synthesis and biological evaluation of N-hydroxy-aminobenzyloxyarylamide analogues as novel selective κ opiod Receptor antagonists
    419. κ opiod Receptor interacts with Na+/H+-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na+ …
    420. Stress-induced epigenetic regulation of κ–opiod Receptor gene involves transcription factor c-Myc
    421. κ–opiod Receptor stimulation inhibits growth of neonatal rat ventricular myocytes
    422. Synthesis and evaluation of novel peripherally restricted κ–opiod Receptor agonists
    423. The novel κ–opiod Receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice
    424. Butorphanol alleviates lipopolysaccharide‑induced inflammation and apoptosis of cardiomyocytes via activation of the κ‑opiod Receptor
    425. The κ–opiod Receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety
    426. Functional evidence for interaction between prostaglandin EP3 and κ–opiod Receptor pathways in tactile pain induced by human immunodeficiency virus type-1 (HIV-1 …
    427. Arylacetamide κ–opiod Receptor agonists produce a tonic-and use-dependent block of tetrodotoxin-sensitive and-resistant sodium currents in colon sensory neurons
    428. Potentiation of κ–opiod Receptor agonist-induced analgesia and hypothermia by fluoxetine
    429. Apparent efficacy of κ–opiod Receptor ligands on serum prolactin levels in rhesus monkeys
    430. Blockade of the morphine-induced increase in turnover of dopamine on the mesolimbic dopaminergic system by κ–opiod Receptor activation in mice
    431. Synthesis and absolute configuration of optically pure enantiomers of a ϰ‐opiod Receptor selective agonist
    432. Na+ ions and Gpp (NH) p selectively inhibit agonist interactions at μ-and κ–opiod Receptor sites in rabbit and guinea-pig cerebellum membranes
    433. Effects of μ-, δ-and κ–opiod Receptor agonists on methamphetamine-induced self-injurious behavior in mice
    434. Early ontogeny of κ–opiod Receptor regulation of prolactin secretion in the rat
    435. Separation of κ–opiod Receptor subtype from frog brain
    436. Transcriptional regulation of the major HIV‐1 coReceptor, CXCR4, by the κ opiod Receptor
    437. κ–opiod Receptor stimulation inhibits cardiac hypertrophy induced by β1-adrenoceptor stimulation in the rat
    438. The effect of κ–opiod Receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
    439. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon κ–opiod Receptor stimulation in the rat heart
    440. Synthesis and pharmacology of a novel κ opiod Receptor (KOR) agonist with a 1, 3, 5-trioxazatriquinane skeleton
    441. Mitochondrial dysfunction and apoptosis are attenuated on κ–opiod Receptor activation through AMPK/GSK-3β pathway after myocardial ischemia and reperfusion
    442. Expression of κ–opiod Receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory changes in …
    443. Impaired [Ca2+]i and pHiresponses to κ–opiod Receptor stimulation in the heart of chronically hypoxic rats
    444. Discovery of N-methyltetrahydroprotoberberines with κ–opiod Receptor agonists-opiod Receptor agonist activities from corydalis yanhusuo WT Wang by using two …
    445. Spontaneous excitatory currents and κ–opiod Receptor inhibition in dentate gyrus are increased in the rat pilocarpine model of temporal lobe epilepsy
    446. Nalfurafine hydrochloride, a selective κ opiod Receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys
    447. … 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[(4′-pyridyl) carboxamido] morphinan (NAP) derivatives as μ/κ opiod Receptor dual selective ligands
    448. Regulation of κ–opiod Receptor mRNA level by cyclic AMP and growth factors in cultured rat glial cells
    449. Structural determinants of diphenethylamines for interaction with the κ opiod Receptor: Synthesis, pharmacology and molecular modeling studies
    450. Baicalein protects chicken embryonic cardiomyocyte against hypoxia–reoxygenation injury via μ-and δ-but not κ–opiod Receptor signaling
    451. Effects of U-69,593, a κ–opiod Receptor agonist, on carrageenin-induced peripheral oedema and Fos expression in the rat spinal cord
    452. κ–opiod Receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 human epithelial tumor cell line
    453. Cholecystokinin octapeptide reverses the κ–opiod–Receptor-mediated depression of calcium current in rat dorsal root ganglion neurons
    454. κ–opiod Receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats
    455. Hypericum perforatum inhibits the binding of μ-and κ–opiod Receptor expressed with the Semliki Forest virus system
    456. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac κ–opiod Receptor stimulation
    457. Effects of acute agonist treatment on subcellular distribution of κ opiod Receptor in rat spinal cord
    458. κ–opiod Receptor modulation of GABAergic inputs onto ventrolateral periaqueductal gray dopamine neurons
    459. Arylacetamide κ opiod Receptor agonists with reduced cytochrome P450 2D6 inhibitory activity
    460. µ-and κ–opiod Receptor activation in the dorsal periaqueductal grey matter differentially modulates panic-like behaviours induced by electrical and chemical …
    461. κ–opiod Receptor stimulation inhibits augmentation of Ca2+ transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes—Role of …
    462. Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ-and κ–opiod Receptor agonists in mice
    463. Effect of μ, δ and κ opiod Receptor agonists on a reactive oxygen species mediated model of skin inflammation
    464. κ–opiod Receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like Receptor agonists
    465. Gi1 and GoA differentially determine kinetic efficacies of agonists for κ–opiod Receptor
    466. The NMDA Receptor antagonist MK-801 differentially modulates μ and κ opiod actions in spinal cord in vitro
    467. The κ–opiod Receptor expressed on the mouse lymphoma cell line R1. 1 contains a sulfhydryl group at the binding site
    468. … to a δ-opiod Receptor messenger rna selectively blocks the antinociception induced by intracerebroventricularly administered δ-, but not μ-, ϵ-, or κ–opiod Receptor …
    469. Conformationally restricted κ–opiod Receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines
    470. Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ-and κ–opiod Receptor agonists in mice
    471. Dual regulation by μ, δ and κ opiod Receptor agonists of K+ conductance of DRG neurons and neuroblastoma× DRG neuron hybrid F11 cells
    472. Decrease of κ–opiod Receptor mRNA level in ventral tegmental area of male mice after repeated experience of aggression
    473. Effect of U50, 488H, a κ–opiod Receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced …
    474. Generalization of NMDA-Receptor antagonists to the discriminative stimulus effects of κ–opiod Receptor agonists U-50,488 H, but not TRK-820 in rats
    475. Effect of κ–opiod Receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats
    476. κ–opiod Receptor activation prevents against arrhythmias by preserving Cx43 protein via alleviation of intracellular calcium
    477. κ–opiod Receptor stimulation induces arrhythmia in the isolated rat heart via the protein kinase C/Na+–H+ exchange pathway
    478. κ–opiod Receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats
    479. Endomorphin-1 Discriminates the μ-opiod Receptor From the δ-and κ–opiod Receptors by Recognizing the Difference in Multiple Regions
    480. Efficacy and safety of a new κ–opiod Receptor agonist for the treatment of uremic pruritus
    481. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488 H, a κ–opiod Receptor agonist, in the mouse
    482. Effects of spiradoline mesylate, a selective κ–opiod–Receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia
    483. Mechanisms involved in the hypotensive effect of a κ–opiod Receptor agonist in hypertensive rats
    484. Promoter activity of mouse κ opiod Receptor gene in transgenic mouse
    485. Peripheral administration of κ–opiod Receptor antagonist stimulates gonadotropin-releasing hormone pulse generator activity in ovariectomized, estrogen-treated …
    486. Efficient synthesis of the κ–opiod Receptor agonist CJ-15,161: four stereospecific inversions at a single aziridinium stereogenic center
    487. Induction of the mouse κ–opiod Receptor gene by retinoic acid in P19 cells
    488. PRO‐AND ANTI‐ARRHYTHMIC EFFECTS OF A κ opiod Receptor AGONIST: A MODEL FOR THE BIPHASIC ACTION OF A LOCAL HORMONE IN THE HEART
    489. κ opiod Receptor stimulation of [35S] GTPγS binding in guinea pig brain
    490. Chronic U50, 488H abolishes inositol 1, 4, 5-trisphosphate and intracellular Ca2+ elevations evoked by κ–opiod Receptor in rat myocytes
    491. … M-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ–opiod Receptor Agonist with an …
    492. The κ–opiod Receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats
    493. Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective κ–opiod Receptor agonist
    494. Prospects of using of κ–opiod Receptor agonists U-50,488 and ICI 199,441 for improving heart resistance to ischemia/reperfusion
    495. Contralateral, ipsilateral and bilateral treatments with the κ–opiod Receptor agonist U-50,488 H in mononeuropathic rats
    496. Diminution of contractile response by κ–opiod Receptor agonists in isolated rat ventricular cardiomyocytes is mediated via a pertussis toxin-sensitive G protein
    497. [Pro3]Dyn A(1−11)-NH2:  A Dynorphin Analogue with High Selectivity for the κ opiod Receptor
    498. Analogs of the κ opiod Receptor antagonist arodyn cyclized by ring-closing metathesis retain κ opiod Receptor affinity, selectivity and κ opiod Receptor antagonism
    499. N-substituted 4β-methyl-5-(3-hydroxyphenyl)-7α-amidomorphans are potent, selective κ opiod Receptor antagonists
    500. Differential effects of μ-opiod, δ-opiod and κ–opiod Receptor agonists on dopamine Receptor agonist-induced climbing behavior in mice
    501. Coupling of the cloned rat κ–opiod Receptor to adenylyl cyclase is dependent on Receptor expression
    502. The amygdala mediates the impairing effect of the selective κ–opiod Receptor agonist U-50,488 on memory in CD1 mice
    503. κ–opiod Receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4+ lymphocytes
    504. Behavioral characterization of κ opiod Receptor agonist spiradoline and cannabinoid Receptor agonist CP55940 mixtures in rats
    505. The κ–opiod Receptor agonist U50, 488H induces acute physical dependence in guinea-pigs
    506. Antagonism of the morphine-induced Straub tail reaction by κ–opiod Receptor activation in mice
    507. Activation of κ–opiod Receptor by U50, 488H improves vascular dysfunction in streptozotocin-induced diabetic rats
    508. Comparative effects of selective κ–opiod Receptor agonists on dopamine levels in the dorsal caudate of freely moving rats
    509. Modification of κ–opiod Receptor agonist-induced antinociception by diabetes in the mouse brain and spinal cord
    510. Process research and scale-up of the κ–opiod Receptor agonist CJ-15,161 drug candidate
    511. Participation of dorsal peria